Lumicell said yesterday it won FDA approval to launch a pilot feasibility study of its intraoperative imaging system for patients with esophageal, colorectal and pancreatic cancers. The study is supported by a grant from the National Cancer Institute’s Spore program, the company said, and will be conducted at Massachusetts General Hospital in Boston. “The launch of […]
Lumicell Diagnostics said it won an investigational device exemption from the FDA for a pilot feasibility trial of its imaging system for breast cancer surgeries.
The study is slated to be conducted at the Mass. General Hospital in Boston, the company said.
Imaging systems maker Lumicell Diagnostics amended a previously closed $1 million funding round after landing another $560,000 in financing from 2 new investors, regulatory filings show.
Lumicell Diagnostics Inc. hit the $1 million goal for its funding round.
Wellesley, Mass.-based Lumicell is developing a hand-held imaging system designed to give physicians a better picture of the amount of cancer remaining at tumor sites during surgery – oncology surgery’s holy grail of “clean margins.”